Anti-ErbB2 / HER2 Affibody® Molecule (FITC)
Be the first to review this product! Submit a review
|
(11 Publications)
Anti-ErbB2 / HER2 Affibody® Molecule (FITC) suitable for Flow Cyt, ICC/IF, IHC-Fr. Cited in 10 publications.
View Alternative Names
CD340, HER2, MLN19, NEU, NGL, ERBB2, Receptor tyrosine-protein kinase erbB-2, Metastatic lymph node gene 19 protein, Proto-oncogene Neu, Proto-oncogene c-ErbB-2, Tyrosine kinase-type cell surface receptor HER2, p185erbB2, MLN 19
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-ErbB2 / HER2 Affibody® Molecule (FITC) (AB31891)
Human mammary gland cell line SK-BR3 cells were stained with fluorescin conjugated Anti-ErbB2 / HER2 Affibody® molecule (ab31891). The staining was localized to the membrane of the ErbB 2 expressing human mammary gland cells. Nuclei were counter stained with DAPI (blue fluorescence). The SK-BR3 cells were stained for 30 minutes at a concentration of 1-5ug Affibody® molecule/ml.
Reactivity data
Product details
This product is a recombinant protein produced in E.coli.
What are Affibody Molecules?
Affibody® affinity ligands are unique research reagents, produced using innovative protein-engineering technologies. They are small, simple proteins composed of a three-helix bundle based on the scaffold of one of the IgG-binding domains of Protein A. Protein A is a surface protein from the bacterium Staphylococcus aureus. This scaffold has excellent features as an affinity ligand and can be designed to bind with high affinity to any given target protein. The domain consists of 58 amino acids, 13 of which are randomized to generate Affibody® libraries with a large number of ligand variants. Thus, the libraries consist of a multitude of protein ligands with an identical backbone and variable surface-binding properties. In function, Affibody® Molecules mimic monoclonal antibodies. Compared to antibodies, the most striking dissimilarity of Affibody® Molecules is the small size. Affibody® Molecules have a molecular weight of 6kDa, compared to the molecular weight of antibodies, which is 150kDa. In spite of its small size, the binding site of Affibody® Molecules is similar to that of an antibody. The advantages of Affibody® Molcules over antibodies are: -their small size -the simple structure of the molecules -its robust physical properties; able to withstand a broad range of analytical conditions, including extreme pH and elevated temperature -its ability to fold correctly intracellularly -the fast and cost effective production in bacteria -the potential to couple Affibody® Molecules in multimeric constructs Affibody® Molecules have highly competitive properties for applications within affinity purification, sample preparation, protein detection and in vitro diagnostics.
Properties and storage information
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The role of ErbB2 extends beyond a singular function. It becomes an active component when forming heterodimers with other EGFR family members such as ErbB3 to initiate various downstream signaling cascades. The dimerization activates intracellular pathways leading to cell proliferation survival differentiation and migration. Within cells ErbB2 influences processes critical for normal development and tissue homeostasis contributing significantly to signal transduction networks.
Pathways
ErbB2 plays a pivotal role in pathways such as the PI3K/Akt and MAPK/ERK pathways. These pathways are important in mediating cellular responses to growth signals. The PI3K/Akt pathway activated by HER2 signaling regulates cell growth and survival while the MAPK/ERK pathway contributes to cell differentiation and proliferation. ErbB2's interaction with proteins like ErbB3 is fundamental in these pathways increasing the amplitude and diversity of downstream signals.
Target data
Publications (11)
Recent publications for all applications. Explore the full list and refine your search
Science advances 10:eadk9944 PubMed39630893
2024
Applications
Unspecified application
Species
Unspecified reactive species
Cancers 12: PubMed33213060
2020
Applications
Unspecified application
Species
Unspecified reactive species
Frontiers in oncology 10:191 PubMed32185126
2020
Applications
Unspecified application
Species
Unspecified reactive species
Oncotarget 9:27736-27751 PubMed29963233
2018
Applications
Unspecified application
Species
Unspecified reactive species
Human pathology 77:35-44 PubMed29555575
2018
Applications
IHC-P
Species
Human
Journal of immunology research 2017:3908289 PubMed29104875
2017
Applications
Flow Cyt
Species
Human
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association 20:416-427 PubMed27517839
2016
Applications
Unspecified application
Species
Unspecified reactive species
Molecular therapy : the journal of the American Society of Gene Therapy 22:1029-38 PubMed24572294
2014
Applications
Unspecified application
Species
Unspecified reactive species
OncoTargets and therapy 6:693-701 PubMed23814468
2013
Applications
Flow Cyt
Species
Human
Molecular oncology 7:440-51 PubMed23290417
2013
Applications
Unspecified application
Species
Unspecified reactive species
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com